Allergan, Inc.

NYSE: AGN
$193.02
+$0.03 (+0.0%)
Closing price May 8, 2020
A new addition to the Merrill Lynch US 1 list, plus four additional stocks that offer a fair degree of safety and solid dependable dividends. With the market volatility spiking, it makes sense to...
The top analyst upgrades, downgrades and initiations seen on Thursday included Allergan, Boeing, Facebook, GoPro, Microsoft, Pfizer, Royal Dutch Shell, ServiceNow and Tiffany.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Allergan, Apple, Carnival, Ciena, Juniper Networks, Lockheed Martin, Plug Power, Take-Two Interactive Software, United...
Tuesday was a down day for the broad U.S. markets. We are now in the busiest week of this earnings season with 12 Dow components reporting. If anything these major companies will set a direction for...
Here are five top health care stocks that provide investors with different avenues to invest in the sector. They all should be solid additions to growth portfolios for 2019.
The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm and Target.
Big Pharma is looking good for investors in the second half of 2018. That's the message from the research team at Bank of America Merrill Lynch.
Golden crosses, typically seen as a bullish sign, recently happened to shares of Tesla and others, while death crosses, a bearish sign, occurred at Schlumberger and others.
The top analyst upgrades, downgrades and other research calls from Thursday include Allergan, Cheniere Energy, Clean Energy, Facebook, Fiat Chrysler, Intel and NetApp.
Merrill Lynch released its high-conviction ideas for the third quarter ahead of the Independence Day holiday. These picks are based on the firm's views of potential significant market and...
There is deep value for long-term investors in these specialty pharmaceutical companies, and the ability to buy in to some of the best companies in the industry at rock bottom pricing.
The top analyst upgrades, downgrades and other research calls from Tuesday include Alcoa, Alphabet, BP, Epizyme, FirstEnergy, First Solar, KeyCorp, Nvidia and Vale.
Here are the latest addition to the Merrill Lynch US 1 list and three current list members that have big upside to their price targets.
Dermira, BRF, Park Hotels & Resorts, and Allergan all posted new 52-week lows Monday.
While chasing what portfolio managers own isn’t always the best idea, many people have made a lot of money by simply mimicking what legendary investors like Warren Buffett hold.